Physician profile
Jason M Nesmith
NPI 1881858686
$3,417.14
in general payments reported to CMS, 2019-2025
30 companies · $672 in 2025
The $672 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $443 · 2020: $259 · 2021: $644 · 2022: $579 · 2023: $389 · 2024: $431 · 2025: $672.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,492.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,491.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $666.90 | 2019-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $538.78 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $322.65 | 2019-2025 | Airsupra, Farxiga |
| Janssen Pharmaceuticals, INC | $298.89 | 2020-2024 | Xarelto |
| Lilly USA, LLC | $183.21 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $175.64 | 2019-2025 | |
| Exact Sciences Corporation | $168.85 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Abbvie INC. | $143.69 | 2019-2025 | |
| Csl Behring | $112.99 | 2022-2025 | Haegarda, Andembry |
| Bayer Healthcare Pharmaceuticals INC. | $100.93 | 2022-2025 | |
| Dexcom, INC. | $94.50 | 2021-2025 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $67.81 | 2020-2023 | Takhzyro |
| Pharming Healthcare, INC. | $61.86 | 2020-2022 | |
| Corcept Therapeutics | $55.13 | 2024 | Korlym |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $47.96 | 2020-2025 | Xifaxan |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $44.07 | 2021 | |
| Novartis Pharmaceuticals Corporation | $39.64 | 2019 | |
| Sanofi Pasteur INC. | $35.35 | 2023 | |
| Amgen INC. | $34.84 | 2024 | Otezla, Repatha |
| Amarin Pharma, INC. | $29.70 | 2019 | |
| Inspire Medical Systems, INC. | $27.46 | 2025 | Inspire |
| Merck Sharp & Dohme LLC | $27.41 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Biohaven Pharmaceuticals, INC. | $26.04 | 2021 | |
| Radius Health, INC. | $23.98 | 2020 | |
| Phathom Pharmaceuticals, INC. | $21.50 | 2025 | Voquezna |
| Grifols USA, LLC | $16.21 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $16.11 | 2022 | |
| Inari Medical, INC. | $14.73 | 2022 | |
| Avion Pharmaceuticals | $13.00 | 2020 | |
| Inogen, INC. | $7.31 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Nesmith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.